Homogenisation process for the preparation of a cellular component homogenate
WO2020212961A1
Method for preparing a biomass of stable freeze-dried bacterial cells and determining the stability thereof by means of a cytofluorometry metho
WO2020212934A1
Use of a cytofluorometry method for evaluating the stability and viability of a biomass of freeze-dried bacterial cells
WO2020178794A1
Mixture of probiotic bacteria strains for use in the treatment of allergic asthma and with recurrent wheezing, preferably in paediatric subjects
KR20200121790A
Composition for treating and/or ameliorating sleep disorders and mood disorders
KR20200121791A
Composition for treating and/or ameliorating sleep disorders and mood disorders
US2020164004A1
Bacterial composition and/or derivatives thereof whose biological activity has been specifically studied for the improvement of the state of health differentiated for males and females
KR20200020850A
Compositions comprising bacterial strains belonging to Lactobacillus salivarius species for treating Parkinson's disease
CN110958884A
Bacterial therapy based on bacterial compositions for the treatment of neurodegenerative diseases
CA3041599A1
Composition for the preventive or curative treatment of liver disorders
US2019255131A1
A composition comprising an extract of irvingia gabonensis and strains of bifidobacteria for regulating and reducing body weight
CN109789171A
For treating the composition of major depressive disorder
KR20190103135A
Uses thereof to prevent, inhibit and / or reduce the formation of lactic acid bacteria and bacterial biofilms
BR112018073924A2
bacterial gel compositions for topical applications and uses thereof
CA3018035A1
Lactic acid bacterial composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, of concurrent fungal infections
WO2017137920A2
Use of bacterial strains belonging to the species lactobacillus kefiri in paediatrics to generate and/or maintain a state of homeostasis
CN108430484A
For showing the bacteria composition of decline after weakening movement
EP3377083A1
Compositions with a synergistic action between a mucoadherent gelling complex against the passage of antigens, and immunomodulatory anti-il17 bacteria for use in the treatment of un¢ related autoimmune and neurodegenerative diseases.
US2019015463A1
Composition of lactic bacteria for use in the treatment of infections due to propionibacterium acnes and in particular for acne
CN107847483A
Antibiotic with particular treatment activity and the Bacillus acidi lactici with identical treatment idicatio with not transferable antibiotic resistance and/or Bifidobacterium at the same associated with apply
